Healthcare M&A has been on a tear in 2014. Not to be left out, Abbott Labs' (NYSE: ABT) recently announced a $2.9 billion acquisition of the Chilean generic drug maker CFR Pharmaceuticals.
This deal is a solid win for Abbott. It gains increased access to the fast growing Latin American market, adds scale to its generic drug business, and will be accretive to next year's earnings.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss the deal details along with why it makes one of the most attractive things about Abbott Labs even better.
